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We evaluated risk factors and treatment outcomes as-
sociated with multidrug-resistant (MDR) and extensively 
drug-resistant (XDR) tuberculosis (TB) in Germany in 2004–
2006. In 177 (4%) of 4,557 culture-positive TB cases, Myco-
bacterium tuberculosis isolates were identifi ed as MDR TB; 
an additional 7 (0.15%) met criteria for XDR TB. Of these 
184 patients, 148 (80%) were born in countries of the former 
Soviet Union. In patients with XDR TB, hospitalization was 
longer (mean ± SD 202 ± 130 vs. 123 ± 81 days; p = 0.015) 
and resistance to all fi rst-line drugs was more frequent (36% 
vs. 86%; p = 0.013) than in patients with MDR TB. Seventy-
four (40%) of these 184 patients received treatment with 
linezolid. Treatment success rates ranged from 59% for the 
entire cohort (59% for MDR TB and 57% for XDR TB) to 
87% for those with a defi nitive outcome (n = 125; 89% for 
MDR TB and 80% for XDR TB). Extensive drug susceptibil-
ity testing and availability of second- and third-line drugs un-
der inpatient management conditions permit relatively high 
treatment success rates in MDR and XDR TB.
Tuberculosis is among the leading causes of death worldwide. The World Health Organization (WHO) 
estimates that 32% of the world population is infected with 
Mycobacterium tuberculosis, the causative agent of TB (1). 
There were an estimated 9.2 million new TB cases and 1.7 
million deaths from TB in 2006 (2).
Drug resistance to isoniazid and rifampin, the 2 most 
potent fi rst-line drugs for the treatment of TB (the defi ni-
tion for MDR), is increasing globally (3,4). Surveillance 
data indicate MDR TB is an emerging global problem, 
especially in countries of the former Soviet Union (FSU), 
Israel, and areas of the People’s Republic of China (5–7). 
Since active TB will develop in only a proportion of per-
sons infected with M. tuberculosis directly after primary 
infection, the prevalence of MDR TB may still be underes-
timated. Furthermore, strains of M. tuberculosis that are re-
sistant to second-line drugs are also emerging. In vitro drug 
resistance of M. tuberculosis to any fl uoroquinolone and 
to at least one of the injectable drugs (capreomycin, kana-
mycin, or amikacin), in addition to isoniazid and rifampin 
resistance, is defi ned as XDR TB (8,9). Strains of XDR TB 
have now been isolated from patients in >45 nations world-
wide, and they are associated with worse treatment out-
comes than strains of MDR TB (8,10,11). Strains of XDR 
TB are increasingly seen in HIV-seropositive persons with 
TB in southern Africa, where these strains are passed by 
person-to person contact. XDR TB has become a serious 
problem for the health administrations in this region (12). 
In contrast, infections with XDR TB strains are rarely seen 
in Western Europe, mainly among the population of pre-
treated migrants from countries of the FSU (13).
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Multidrug- and Extensively Drug-Resistant Tuberculosis
Although the incidence of TB is steadily declining in 
Germany, numbers of cases with MDR TB strains are in-
creasing. In 2006, of 3,501 TB cases in Germany for which 
resistance data were available, 78 (2.2%) were MDR TB 
(14); these cases mainly occurred among immigrants from 
countries with high prevalence of MDR TB (14,15).
TB surveillance data for Germany are reported annu-
ally by a national disease surveillance center, the Robert 
Koch Institute (14). However, data on MDR TB are only 
reported for in vitro fi rst-line drug resistance against isoni-
azid, rifampin, ethambutol, pyrazinamide, and the inject-
able agent streptomycin. To ascertain risk factors associ-
ated with MDR and XDR TB and to evaluate treatment 
outcome in relation to level of drug resistance and level of 
care, we performed a retrospective survey among the net-
work of hospitals participating in the Tuberculosis Network 
European Trials group (TBNET); these hospitals specialize 
in treating TB in Germany. 
Materials and Methods
Clinical outcomes (available from the original clini-
cal records) were evaluated by attending physicians at 
hospitals specialized in the care of patients with TB in 
Germany; they completed a standard questionnaire for 
all patients with culture-confi rmed isoniazid and rifampin 
drug-resistant M. tuberculosis hospitalized from January 
1, 2004, through December 31, 2006. The survey included 
information on the patients’ age, gender, country of origin, 
HIV-seropositivity status, history of previous treatment, 
M. tuberculosis drug-resistance profi le, treatment duration, 
and treatment outcome. Drug-susceptibility testing (DST) 
for fi rst-line anti-TB drugs was performed by quality-
assured laboratories. Isolates with resistances to anti-TB 
drugs were (re-)tested at one of the WHO’s Supranational 
Reference Laboratories in Borstel or Gauting (16). DST for 
second-line drugs (ethionamide, amikacin, capreomycin, 
p-aminosalicylic acid, cycloserine, kanamycin) or third-
line drugs (linezolid) were exclusively performed in 1 of 
the 2 reference centers. The BACTEC MGIT 960 (Bec-
ton Dickinson Diagnostic Systems, Sparks, MD, USA) 
was used for DST of fi rst-line drugs and BACTEC MGIT 
960 or the proportion method on Lowenstein–Jensen me-
dium, or both, was used for DST of second- and third-line 
drugs. XDR TB was defi ned as resistance to isoniazid and 
rifampin (MDR TB defi nition), a fl uoroquinolone, and at 
least one of the injectable anti-TB drugs capreomycin, ka-
namycin, or amikacin (17). MDR TB cases with isolates 
resistant to all fi rst-line drugs were defi ned as those resis-
tant to isoniazid, rifampin, ethambutol, streptomycin and, 
when tested, pyrazinamide.
According to Laserson criteria, a patient was defi ned as 
“cured” when he or she had completed treatment according 
to the country protocol and had been consistently culture-
negative (with at least 5 results) for the fi nal 12 months of 
treatment; “treatment completed” when he or she had com-
pleted treatment according to the country protocol but did 
not meet the defi nition for cure or treatment failure or bac-
teriologic results were missing (i.e., <5 cultures were per-
formed in the fi nal 12 months of therapy) (18). Outcomes 
were compared by using the χ2 test or Fisher exact test (cat-
egorical variables) in cases achieving a fi nal outcome (dif-
ferent from default, transferred out, or still on treatment), 
and by using the Kaplan-Meier curve where appropriate. 
Logistic regression analysis was performed. The following 
variables were included in the statistical analysis: country, 
gender, HIV seropositivity, immigrant status, previous TB 
treatment for >30 days, DST results (ethambutol, pyrazin-
amide, streptomycin, any fl uoroquinolone, any injectable 
second-line drug), and resistance to all second-line drugs. 
A patient was considered HIV positive, when results of the 
HIV-antibody ELISA (once) and at least 1 confi rmatory 
test (Western blot or nucleic acid amplifi cation technique) 
were positive.
Results
Among 4,557 culture-confi rmed TB cases at 27 par-
ticipating hospitals (representing 37% of all culture-con-
fi rmed cases in Germany in the 3-year period 2004–2006), 
184 (4%) M. tuberculosis isolates were in vitro resistant 
at least to isoniazid and rifampin. They MDR TB isolates 
represented 65% of all MDR and XDR TB cases diagnosed 
in Germany in the study period (14,19,20). Of these cases, 
177 were MDR TB, and 7 were XDR TB.
Of the 184 study patients, 174 (95%) had M. tuber-
culosis isolates resistant to streptomycin, 119 (65%) to 
ethambutol, 103 (56%) to rifabutin, 79 (43%) to pyrazin-
amide, 23 (13%) to amikacin, 20 (11%) to a fl uoroquinolo-
ne, 19 (10%) to capreomycin, 36 (19%) to ethionamide, 15 
(8%) to para-aminosalicylic acid, 9 (5%) to cycloserine, 3 
(2%) to kanamycin, and 1 (<1%) to linezolid. Demographic 
and clinical characteristics are described in Table 1 and the 
online Appendix Table (available from www.cdc.gov/EID/
content/14/11/1700-appT.htm).
Forty-fi ve (24%) patients with MDR TB strains were 
female (median age 28 years), and 139 (76%) were male 
(median age 39 years). HIV testing was performed for 142 
(80%) of 177 patients with MDR TB and 4 (57%) of 7 pa-
tients with XDR TB. Seven patients with MDR TB (4.9%) 
and no patient with XDR TB tested positive for HIV-1. 
Notably, 148 (80.4%) of 184 patients with MDR TB 
were immigrants from the FSU (online Appendix Figure, 
available from www.cdc.gov/EID/content/14/11/1700-
appG.htm).
Ninety-four (53%) patients with MDR TB and 6 (86%) 
patients with XDR TB had previously received anti-TB 
treatment for >1 month (p = 0.08). Of the 100 previous-
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ly treated patients, 89% were immigrants from the FSU, 
6% from other countries, and 5% were born in Germany. 
Only 1 of the 7 patients with XDR TB had previously re-
ceived directly observed treatment. Strains from patients 
with XDR TB had a signifi cantly higher probability to be 
resistant to all fi rst-line drugs (isoniazid, rifampin, pyrazin-
amide, ethambutol) (6/7, 85.7% vs. 64/177, 36%; p = 0.08) 
than strains from other patients with MDR TB. The median 
time from the onset of treatment to conversion of smear mi-
croscopy and culture to negative results was 88 days (mean 
± SD 129.8 ± 129.2 days) and 117 days (mean ± SD 141 ± 
99.7 days), respectively, with XDR TB vs. 53.5 days (mean 
± SD 69.4 ± 76.1 days) and 61.5 days (mean ± SD 81.3 ± 
74.6 days), respectively, with MDR TB.
Of 177 patients with MDR TB, 14 (7.9%) died, one’s 
treatment failed (0.6%), 105 (59.3%) were treated suc-
cessfully (6/105 underwent surgery), 31 (17.5%) were still 
receiving treatment, and 26 (14.7%) were lost to follow-
up. Of 7 patients with XDR TB, 4 (57.1%) were treated 
successfully (1/6 underwent surgery), 2 (28.6%) were still 
receiving treatment, and 1 (14.3%) died.
The overall treatment success including all patients 
was 59.2% (59.3% for patients with MDR TB and 57.1% 
for patients with XDR TB). After the 26 patients lost to 
follow-up were removed from the analysis, the treatment 
success rate increased to 69% (69.5% for patients with 
MDR TB and 57.1% for patients with XDR TB). When 
we also removed the 33 patients still receiving treatment, 
the treatment success rate increased to 87.2% (87.5% for 
patients with MDR TB and 80% for patients with XDR 
TB). Patients with XDR TB were less likely to achieve 
sputum-smear and culture conversion (5/7, 71.4% vs. 
142/177, 80.2%; p = 0.63) and required a longer duration 
of hospitalization (mean ± SD 202 ± 130 vs. 123.3 ± 81.0 
days, p = 0.015) than patients with MDR TB. Logistic re-
gression analysis of the association of treatment failure 
(death or failure) with potential covariates was performed; 
no statistical signifi cant odds ratio was obtained on either 
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Table 1. Demographic and clinical characteristics of 184 patients with MDR TB and XDR TB, Germany* 
Variables
MDR TB,
n = 177
XDR TB,
n = 7 p value 95% CI
Male gender, no. (%) 133 (75.1) 6 (85.7) 0.54 –0.37 to 0.17
Age, y, mean ± SD 37.7 ± 15.4 42.4 ± 11.9 0.42 –16.33 to 6.93
Country of birth, no. (%) 
 Former Soviet Union 142 (80.2) 6 (85.7) 0.74 –0.32 to 0.22
 Germany 11 (6.2) – – –
 Others 24 (13.6) 1 (14.3) 0.93 –0.27 to 0.25
HIV positive, no. (%) 7/142 (4.9) 0 0.54 0.01 to 0.08
Kind of TB, no. (%) 
 Pulmonary TB 162 (91.5) 6 (85.7) 0.59 –0.2 to 0.32
 Extrapulmonary TB 5 (2.9) – – –
 Pulmonary and extrapulmonary TB 10 (5.6) 1 (14.3) 0.29 –0.34 to 0.16
Days in hospital, mean ± SD 123.3 ± 81 202 ± 130 0.015† –141.8 to –15.53
Previous TB treatment, no. (%) 94 (53) 6 (86) 0.08 –0.59 to 0.06
Resistance to all first-line drugs, no. (%) 64 (36) 6 (85.7) 0.008 –0.76 to –0.21
Resistance to fluoroquinolones, no. (%) 13/162 (8) 7 (100) <0.001† –0.96 to –0.87
Resistance to injectable second-line drugs, no. (%) 21/164 (12.8) 7 (100) <0.001† –0.92 to –0.83
Linezolid treatment, no. (%) 69 (39) 5 (71.4) 0.09 –0.66 to 0.02
Treatment outcome, no. (%) 
 Cured 79 (44.6) 3 (42.8) 0.91 –0.35 to 0.39
 Completed 26 (14.7) 1 (14.3) 1 –0.26 to 0.26
 Successful treatment (cured + completed) 105 (59.3)  4 (57.1) 0.91 –0.35 to 0.39
 Died 14 (7.9) 1 (14.3) 0.4 –0.32 to 0.18
 Failure 1 (0.6) – – –
 Treatment failure (death or failure) 15 (8.4) 1 (14.3) 0.57 –0.32 to 0.2
 Default 1 (0.6) – – –
 Transferred out 25 (14.1) – – –
 Uncertain outcome (default + transferred out) 26 (14.7) – – –
 Still on treatment 31 (17.5) 2 (28.6) 0.45 –0.44 to 0.22
Duration of therapy from beginning MDR treatment, mo, mean ± SD 18 ± 9 20 ± 5 0.56 –8.78 to 4.78
Sputum smear conversion, no. (%) 98 (55.4) 5 (71.4) 0.4 –0.5 to 0.18
Culture conversion, no. (%) 132 (74.6) 5 (71.4) 0.85 –0.31 to 0.37
Sputum smear conversion, d, mean ± SD 69.4 ± 76 129.8 ± 129.2 0.09 –132 to 11.2
Culture conversion, d, mean ± SD 81.3 ± 74.6 141 ± 99.7 0.08 –127.6 to 8.2
*MDR, multidrug-resistant; TB, tuberculosis; XDR, extensively drug-resistant; CI, confidence interval. 
†Significant result (p<0.05). 
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the univariate or multivariate analysis; a negative progno-
sis related to several variables could be seen, but sample 
size might have infl uenced the statistical results (Table 2). 
Treatment outcomes were compared between patients who 
were never treated and those who were previously treated 
with anti-TB drugs; no statistically signifi cant difference 
was evident between the 2 groups (Table 3).
Seventy-four (40.2%) of the 184 study patients were 
treated with linezolid. Fifty-eight (78.4%) of them were born 
in the FSU, and 44 (59.5%) had received previous treatment. 
Two (2.7%) were HIV seropositive. M. tuberculosis isolates 
of patients receiving linezolid treatment were more fre-
quently resistant to pyrazinamide (49/74, 66.2% vs. 30/110, 
27.3%; p<0.001), capreomycin (16/74, 21.6% vs. 3/110, 
2.7%; p<0.001), amikacin (15/74, 20.8% vs. 8/110, 7.3; 
p = 0.009), fl uoroquinolones (14/74, 18.9% vs. 6/110, 5.5%; 
p = 0.004) and cycloserine (6/74, 8.1% vs. 3/110, 2.7%; p = 
0.16). Patients with XDR TB were more frequently treated 
with linezolid (5/7, 71.4% vs. 69/177, 38.9%; p = 0.12) 
than other patients with MDR TB. In the group of patients 
with linezolid treatment, the median time to sputum-smear 
conversion (XDR TB: 134 days vs. 44 days; MDR TB: 
57 days vs. 36.5 days; log rank p = 0.0213) and to culture 
conversion (XDR TB: 160 days vs. 105 days; MDR TB: 
68 days vs. 59 days; log rank p = 0.0023) was longer than 
in the group of patients not receiving linezolid (Figure). 
However, the duration of hospitalization was comparable 
in both groups (mean ± SD 135.4 ± 84.1 days with lin-
ezolid vs.120.5 ± 84.2 days without linezolid; p = 0.241) 
as was the case-fatality rate (p = 0.28). Different outcomes 
(e.g., successful treatment) were identifi ed between those 
treated with linezolid versus those without linezolid (Table 
4). Adverse effects ascribed to linezolid were observed in 
25 (33.8%) of 74 cases (35% in cases with MDR-and 20% 
in cases with XDR TB). Linezolid was interrupted in 19 
(76%) of 25 cases and not reintroduced in 11 (58%) of 19 
cases. Severe anemia appeared in 14 (56%) of 25 cases.
Sixty-four (36.2%) of 177 MDR TB patients showed 
resistance to pyrazinamide, ethambutol, or both. These pa-
tients were less likely to achieve sputum-smear and culture 
conversion (49 [77%] of 64 vs. 93 [82%] of 113; p = 0.36) 
and were more frequently treated with linezolid (38 [60%] 
of 64 vs. 31 [27%] of 113; p = 0.00003). Thirty (47%) of 
them were successfully treated, 19 (30%) were still receiv-
ing treatment, one’s treatment failed (2%), 10 (16%) were 
lost to follow-up, and 4 died (6%). Of 7 patients with XDR 
TB, 6 (86%) harbored strains that were resistant to pyrazi-
namide and ethambutol. Three (50%) of them achieved 
successful treatment outcome, 2 (33%) were still receiving 
treatment, and 1 (16.7%) died. These patients with XDR 
TB required longer hospitalization than those with MDR 
TB with resistance to pyrazinamide and ethambutol (mean 
± SD 210.7 ± 140.1 vs. 132.5 ± 92.8 days; p = 0.063).
Discussion
We present the results of our national survey on clini-
cal parameters associated with MDR and XDR TB in a 
Western European country. Of the patients hospitalized 
with MDR or XDR TB in Germany who were included in 
this survey, 53% were treated previously against TB, and 
nearly 90% of them had immigrated from FSU countries. 
Relatively high treatment success rates were achieved with 
conventional medical treatment, intensifi ed medical care, 
including long-term inpatient treatment, directly observed 
therapy, and use of third-line anti-TB drugs. Less then 6% 
of patients with MDR TB required a surgical intervention.
In the German observational cohort, the proportion of 
MDR TB among all TB cases was 4%. Strains of M. tuber-
culosis in 7 (3.8%) of 184 patients with MDR TB met the 
case defi nition for XDR TB, an infection now recognized 
as a global problem (10). Alarming reports on the spread 
of XDR TB among HIV-seropositive persons have been 
published recently for Kwa Zulu Natal, South Africa (12). 
While HIV coinfection was not a risk factor for XDR TB 
in our cohort, XDR TB was related to previous treatment 
mismanagement including the lack of directly observed 
therapy in FSU countries.
Patients with XDR TB have a higher risk for death and 
treatment failure than those with MDR TB (21,22). In infec-
tions with MDR TB, drug resistance to additional fi rst-line 
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Table 2. Logistic regression analysis of the association of treatment failure (death and failure) with potential explanatory factors* 
Variables Crude OR (95% CI) Adjusted OR (95% CI)
Male gender 4.46 (0.56–35.5) 5.8 (0.61–56.6)
Age, y 1.05 (1.01–1.09) 1.06 (1.01–1.1)
Immigrant status 1.18 (0.13–10.2) 0.7 (0.07–6.6)
HIV seropositivity 5 (0.76–32.6) 2.5 (0.28–22.1)
Previous anti-TB treatment >30 d  0.7 (0.26–2.2) 0.4 (0.11–1.3)
Streptomycin resistance 1.35 (0.15–11.4) 1.18 (0.13–10.69)
Ethambutol resistance 1.74 (0.52–5.7) 0.99 (0.29–3.3)
Pyrazinamide resistance 1.65 (0.57–4.7) 1.08 (0.35–3.3)
Fluoroquinolone resistance 1.67 (0.32–8.6) 0.86 (0.09–7.7)
Resistance to injectable second-line drugs 1.16 (0.3–4.5) 1.28 (0.31–5.2)
Resistance to all second-line drugs 1.18 (0.34–3.9) 1.35 (0.37–4.8)
*OR, odds ratio; CI, confidence interval; TB, tuberculosis. 
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drugs other than isoniazid and rifampin has recently been 
shown to be a predictor of negative treatment outcomes 
(13). Resistance to fl uoroquinolones and injectable second-
line drugs (capreomycin in particular) also contributes to 
increased risk for treatment failure and death in these cases 
(23,24). XDR TB–defi ning drugs are those considered es-
sential to achieve successful outcomes in MDR TB cases 
(9,17,24,25). While rapid direct sensitivity testing of M. 
tuberculosis for all cases with a suspicion of multidrug 
resistance is highly important, this technology is currently 
not available in many geographic areas with a high inci-
dence of MDR TB.
Our fi ndings support the observation that treatment 
success in cases with MDR TB is dependent on the number 
of drugs the strain is resistant to and the previous treatment 
history. The probability to observe any TB drug resistance 
or MDR TB has been shown to be 4-fold and 10-fold high-
er when patients have received TB treatment in the past 
(8,26,27).
As expected, patients infected with strains of XDR TB 
and MDR TB resistant to all fi rst-line drugs were more likely 
to have a poor treatment outcome than patients infected with 
other strains of multidrug-resistant M. tuberculosis. Patients 
with XDR TB required longer hospitalization and were less 
likely to achieve sputum-smear and culture conversion, al-
though the latter result was not statistically signifi cant.
More than 40% of patients in this cohort received off-
label treatment against MDR or XDR TB with the oxazo-
lidinone linezolid (28). In vitro and pharmacogenetic data 
suggest that oxazolidinones could be useful in management 
of mycobacterial infection, including MDR TB (29–32). 
However, clinical experience with the use of linezolid in the 
management of mycobacterial infections has been mainly 
restricted to case reports in nontuberculous mycobacterial 
diseases (33–35) and to a few case reports on patients with 
MDR TB (28,36,37). Cases of 24 patients with mycobacte-
rial infections who were treated with linezolid were recent-
ly reviewed (38). Sterilization of mycobacterial cultures or 
resolution of symptoms was achieved in 15 (62.5%) of the 
24 cases, although serious adverse events were observed in 
up to 75% of patients.
In this study, the description of 74 patients who were 
treated with linezolid against MDR or XDR TB in routine 
clinical practice substantially adds to the knowledge of the 
effi cacy and tolerability of this drug. Drug toxicity from li-
nezolid occurred in more than one third of patients and lead 
to treatment discontinuation in 76% of them. Patients who 
were treated with linezolid had a much higher level of drug 
resistance than those who were not treated with this drug, 
and they had a longer time to sputum-smear and culture 
conversion. Nevertheless, patients who were treated with a 
linezolid-containing regimen experienced a sustained cul-
ture conversion rate of almost 80%. Despite the fact that 
patients who were treated with linezolid had a much higher 
level of drug resistance, the mortality rate was comparable 
to that of patients with fewer drug resistances who were 
not treated with linezolid. Drug resistance to linezolid in 
cases never treated previously (occasionally reported) (39) 
was extremely low in this cohort (1/184 patients with MDR 
TB). These data suggest that a linezolid-containing com-
bination treatment might be an effective option against 
MDR or XDR TB. However, the high frequency of adverse 
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Table 3. TB treatment outcomes in study patients not previously treated for TB compared with those treated previously for TB* 
Treatment outcomes
No. (%) patients not 
treated previously, n = 84
No. (%) patients treated 
previously, n = 100 p value 95% CI
Cured 40 (47.6) 42 (42) 0.49 ?0.09 to 0.19
Completed 8 (9.5) 19 (19) 0.05 ?0.19 to ?0.001
Successful treatment (cured + completed) 48 (57) 61 (61) 0.58 ?0.18 to 0.1
Died 7 (8.3) 8 (8) 1 ?0.07 to 0.07
Failure 1 (1.19) – – –
Treatment failure (death or failure) 8 (9) 8 (8) 0.8 ?0.07 to 0.09
Default – 1 (1) – –
Transferred out 13 (15.5) 12 (12) 0.55 ?0.06 to 0.12
Uncertain outcome (default + transferred out) 13 (15.5) 13 (13) 0.69 ?0.08 to 0.12
Still receiving treatment 15 (17.9) 18 (18) 0.85 ?0.12 to 0.1
*TB, tuberculosis; CI, confidence interval. 
Figure. Kaplan-Meier plot showing the time to sputum smear 
conversion according to treatment received (linezolid-containing 
regimen, n = 74, vs. linezolid-sparing regimen, n = 110) in Germany 
(log-rank test 0.0924). The proportion of case-patients reaching 
conversion is shown along the vertical axis.
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effects to linezolid warrants extreme caution when this 
drug is used for a prolonged period. Further investigations 
are needed to determine the best duration and dosage of 
linezolid treatment if the drug is to be routinely used as a 
life-saving therapy in cases of MDR or XDR TB.
In this cohort, most patients with MDR TB for whom 
complete treatment data were available were treated for a 
24-month period with a combination treatment of 4 or 5 
effective drugs. Long-term inpatient care (mean ± SD 202 
± 130 days for XDR TB and 123.3 ± 81.0 days for MDR 
TB) and availability of all third-line drugs was necessary to 
achieve an overall treatment success rate of 59% (overall 
sample) to 87% (excluding patients still receiving treat-
ment and lost to follow-up) in the German TBNET hospi-
tals. The results are consistent with those of previous stud-
ies showing overall treatment success rates in MDR TB of 
54% (13) and 62% (40).
The study has several limitations. Fourteen percent of 
patients were lost to follow-up by their hospital physicians. 
Their clinical outcome is uncertain. Complete data on pre-
vious treatment regimens were not available for most pa-
tients with recurrent TB who immigrated from FSU coun-
tries. Additional factors, including variability of provider 
treatment practices in the patients’ native countries and 
existence of additional co-existing conditions, may have 
confounded the results of our analysis. The proportion 
of patients with strains of M. tuberculosis with more ad-
vanced drug resistance was higher among the 27 participat-
ing hospitals of the German TBNET than other hospitals in 
Germany, which are not specialized in TB treatment. Data 
for 35% of patients with MDR TB who were identifi ed in 
Germany during the time of the survey were not available 
for this study as their cases were not diagnosed and treated 
in a hospital participating in this survey, which could have 
resulted in a selection bias. Nevertheless, the large and rep-
resentative sample size, the availability of treatment out-
comes, and the quality of laboratory data (all XDR TB–de-
fi ning drugs tested and drug susceptibility tests controlled 
for quality) strengthen the results of this study.
In conclusion, cases of MDR and XDR TB in Germa-
ny appear to be largely restricted to immigrants from FSU 
countries. Previous treatment mismanagement is the prob-
able cause of M. tuberculosis drug-resistance selection in 
most of these patients. Off-label treatment with linezolid is 
frequently used to treat advanced cases of MDR and XDR 
TB in Germany, despite high rates of adverse effects and 
paucity of clinical evidence for safety, tolerability, and ef-
fi cacy of this medication. Relatively high sustained culture 
conversion rates can still be achieved in advanced cases 
of MDR and XDR TB; this requires high level, labor-in-
tensive, and costly case management, including quality-
controlled drug-susceptibility testing for all second-line 
drugs, long-term inpatient care, directly observed therapy, 
and availability of all third-line drugs. However, these re-
sources are currently not available for patients with MDR 
or XDR TB in many other places outside Western Europe.
Dr Eker, after an appointment at the State of Schleswig-Hol-
stein (Germany) Central Institution for Asylum-seekers, began a 
residency in Internal Medicine/Pulmonary Medicine at the Medi-
cal Clinic of the Research Center Borstel in 2007, where she is 
affi liated with the Division of Clinical Infectious Diseases. She is 
a member of TBNET.
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